{"id":"https://openalex.org/W1802218256","doi":"https://doi.org/10.1056/nejmoa042760","title":"Pegaptanib for Neovascular Age-Related Macular Degeneration","display_name":"Pegaptanib for Neovascular Age-Related Macular Degeneration","publication_year":2004,"publication_date":"2004-12-29","ids":{"openalex":"https://openalex.org/W1802218256","doi":"https://doi.org/10.1056/nejmoa042760","mag":"1802218256","pmid":"https://pubmed.ncbi.nlm.nih.gov/15625332"},"language":"en","primary_location":{"id":"doi:10.1056/nejmoa042760","doi":"https://doi.org/10.1056/nejmoa042760","is_oa":true,"landing_page_url":"https://doi.org/10.1056/nejmoa042760","pdf_url":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa042760?articleTools=true","source":{"id":"https://openalex.org/S62468778","display_name":"New England Journal of Medicine","issn_l":"0028-4793","issn":["0028-4793","0096-6762","1533-4406","2331-4710"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320239","host_organization_name":"Massachusetts Medical Society","host_organization_lineage":["https://openalex.org/P4310320239"],"host_organization_lineage_names":["Massachusetts Medical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"New England Journal of Medicine","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa042760?articleTools=true","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5011881123","display_name":"Evangelos S. Gragoudas","orcid":"https://orcid.org/0000-0002-2437-5283","observed_orcids":["https://orcid.org/0000-0002-2437-5283"]},"institutions":[{"id":"https://openalex.org/I1287163989","display_name":"Massachusetts Eye and Ear Infirmary","ror":"https://ror.org/04g3dn724","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1287163989"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Evangelos S. Gragoudas","raw_affiliation_strings":["Retina Service, Massachusetts Eye and Ear Infirmary and Harvard Medical School, 243 Charles St., Boston, MA 02114, USA. evangelos_gragoudas@meei.harvard.edu","Massachusetts Eye and Ear Infirmary, Boston"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Retina Service, Massachusetts Eye and Ear Infirmary and Harvard Medical School, 243 Charles St., Boston, MA 02114, USA. evangelos_gragoudas@meei.harvard.edu","institution_ids":["https://openalex.org/I1287163989","https://openalex.org/I136199984"]},{"raw_affiliation_string":"Massachusetts Eye and Ear Infirmary, Boston","institution_ids":["https://openalex.org/I1287163989"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085600986","display_name":"Anthony P. Adamis","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anthony P. Adamis","raw_affiliation_strings":["Eyetech Pharmaceuticals, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eyetech Pharmaceuticals, New York","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110271174","display_name":"Emmett T. Cunningham","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Emmett T. Cunningham","raw_affiliation_strings":["Boston"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boston","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109526044","display_name":"Matthew Feinsod","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Matthew Feinsod","raw_affiliation_strings":["Eyetech Pharmaceuticals, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eyetech Pharmaceuticals, New York","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5107839602","display_name":"David R. Guyer","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David R. Guyer","raw_affiliation_strings":["Eyetech Pharmaceuticals, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eyetech Pharmaceuticals, New York","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":185.6766,"has_fulltext":true,"cited_by_count":2416,"citation_normalized_percentile":{"value":1.0,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":99,"max":100},"biblio":{"volume":"351","issue":"27","first_page":"2805","last_page":"2816"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10170","display_name":"Retinal Diseases and Treatments","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10170","display_name":"Retinal Diseases and Treatments","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11377","display_name":"Retinal and Macular Surgery","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11194","display_name":"Ocular Diseases and Beh\u00e7et\u2019s Syndrome","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pegaptanib","display_name":"pegaptanib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/neovascular-age-related-macular-degeneration","display_name":"neovascular age-related macular degeneration","score":0.9940000176429749},{"id":"https://openalex.org/keywords/anti-vegf-therapy","display_name":"anti-VEGF therapy","score":0.9789999723434448},{"id":"https://openalex.org/keywords/intravitreal-injection","display_name":"intravitreal injection","score":0.9769999980926514},{"id":"https://openalex.org/keywords/visual-acuity","display_name":"visual acuity","score":0.7400000095367432},{"id":"https://openalex.org/keywords/dose-response-relationship","display_name":"dose-response relationship","score":0.6140000224113464},{"id":"https://openalex.org/keywords/endophthalmitis","display_name":"endophthalmitis","score":0.9110000133514404},{"id":"https://openalex.org/keywords/retinal-detachment","display_name":"retinal detachment","score":0.8579999804496765},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7730000019073486},{"id":"https://openalex.org/keywords/treatment-efficacy","display_name":"treatment efficacy","score":0.4189999997615814},{"id":"https://openalex.org/keywords/retinal-neovascularization","display_name":"retinal neovascularization","score":0.5460000038146973},{"id":"https://openalex.org/keywords/choroidal-neovascularization","display_name":"choroidal neovascularization","score":0.796999990940094},{"id":"https://openalex.org/keywords/macular-edema","display_name":"macular edema","score":0.593999981880188},{"id":"https://openalex.org/keywords/retinal-pigment-epithelium","display_name":"retinal pigment epithelium","score":0.5410000085830688}],"concepts":[{"id":"https://openalex.org/C2777512022","wikidata":"https://www.wikidata.org/wiki/Q409935","display_name":"Pegaptanib","level":5,"score":0.9684851169586182},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9241650104522705},{"id":"https://openalex.org/C2776403814","wikidata":"https://www.wikidata.org/wiki/Q27429789","display_name":"Macular degeneration","level":2,"score":0.7962565422058105},{"id":"https://openalex.org/C2778257484","wikidata":"https://www.wikidata.org/wiki/Q555066","display_name":"Visual acuity","level":2,"score":0.7412933707237244},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5501287579536438},{"id":"https://openalex.org/C118487528","wikidata":"https://www.wikidata.org/wiki/Q161437","display_name":"Ophthalmology","level":1,"score":0.536962628364563},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.4641735553741455},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.4224720597267151},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.3266025483608246},{"id":"https://openalex.org/C2781100027","wikidata":"https://www.wikidata.org/wiki/Q414270","display_name":"Ranibizumab","level":4,"score":0.1683795154094696},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.14771142601966858}],"mesh":[{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007267","descriptor_name":"Injections","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D008268","descriptor_name":"Macular Degeneration","qualifier_ui":"Q000000981","qualifier_name":"diagnostic imaging","is_major_topic":false},{"descriptor_ui":"D008268","descriptor_name":"Macular Degeneration","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009841","descriptor_name":"Oligonucleotides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D009841","descriptor_name":"Oligonucleotides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D010778","descriptor_name":"Photochemotherapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011446","descriptor_name":"Prospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011859","descriptor_name":"Radiography","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014792","descriptor_name":"Visual Acuity","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D014822","descriptor_name":"Vitreous Body","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020256","descriptor_name":"Choroidal Neovascularization","qualifier_ui":"Q000000981","qualifier_name":"diagnostic imaging","is_major_topic":false},{"descriptor_ui":"D020256","descriptor_name":"Choroidal Neovascularization","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D042461","descriptor_name":"Vascular Endothelial Growth Factor A","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D052157","descriptor_name":"Aptamers, Nucleotide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":6,"locations":[{"id":"doi:10.1056/nejmoa042760","doi":"https://doi.org/10.1056/nejmoa042760","is_oa":true,"landing_page_url":"https://doi.org/10.1056/nejmoa042760","pdf_url":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa042760?articleTools=true","source":{"id":"https://openalex.org/S62468778","display_name":"New England Journal of Medicine","issn_l":"0028-4793","issn":["0028-4793","0096-6762","1533-4406","2331-4710"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320239","host_organization_name":"Massachusetts Medical Society","host_organization_lineage":["https://openalex.org/P4310320239"],"host_organization_lineage_names":["Massachusetts Medical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"New England Journal of Medicine","raw_type":"journal-article"},{"id":"pmid:15625332","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15625332","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The New England journal of medicine","raw_type":"Clinical Trial"},{"id":"pmh:oai:dare.uva.nl:openaire_cris_publications/1a482e79-2a38-4336-85b2-eef4b6e507a9","doi":null,"is_oa":false,"landing_page_url":"https://handle.uba.uva.nl/personal/pure/en/publications/pegaptanib-for-neovascular-agerelated-macular-degeneration(1a482e79-2a38-4336-85b2-eef4b6e507a9).html","pdf_url":null,"source":{"id":"https://openalex.org/S4306400088","display_name":"UvA-DARE (University of Amsterdam)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I887064364","host_organization_name":"University of Amsterdam","host_organization_lineage":["https://openalex.org/I887064364"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Gragoudas, E S, Adamis, A P, Cunningham, E T, Feinsod, M, Guyer, D R, Study group members AMC & Schlingemann, R O 2004, 'Pegaptanib for neovascular age-related macular degeneration', The New England journal of medicine, vol. 351, no. 27. < http://stgr >","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:pure.amsterdamumc.nl:openaire_cris_publications/4b4aae36-edcc-4436-9a6a-535003972a0b","doi":null,"is_oa":false,"landing_page_url":"https://pure.amsterdamumc.nl/en/publications/4b4aae36-edcc-4436-9a6a-535003972a0b","pdf_url":null,"source":{"id":"https://openalex.org/S7407055222","display_name":"Pure Amsterdam UMC","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Gragoudas, E S, Adamis, A P, Cunningham, E T, Feinsod, M, Guyer, D R & AUTHOR GROUP 2004, 'Pegaptanib for neovascular age-related macular degeneration', New England journal of medicine, vol. 351, no. 27, pp. 2805-2816. https://doi.org/10.1056/NEJMoa042760","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:uvapub:oai:dare.uva.nl:publications/1a482e79-2a38-4336-85b2-eef4b6e507a9","doi":null,"is_oa":true,"landing_page_url":"https://dare.uva.nl/personal/pure/en/publications/pegaptanib-for-neovascular-agerelated-macular-degeneration(1a482e79-2a38-4336-85b2-eef4b6e507a9).html","pdf_url":null,"source":{"id":"https://openalex.org/S4306401843","display_name":"Data Archiving and Networked Services (DANS)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1322597698","host_organization_name":"Royal Netherlands Academy of Arts and Sciences","host_organization_lineage":["https://openalex.org/I1322597698"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"The New England journal of medicine, 351(27). Massachussetts Medical Society","raw_type":"info:eu-repo/semantics/article"},{"id":"mag:2262759767","doi":null,"is_oa":false,"landing_page_url":"https://www.sid.ir/En/Journal/ViewPaper.aspx?ID=146035","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":{"id":"doi:10.1056/nejmoa042760","doi":"https://doi.org/10.1056/nejmoa042760","is_oa":true,"landing_page_url":"https://doi.org/10.1056/nejmoa042760","pdf_url":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa042760?articleTools=true","source":{"id":"https://openalex.org/S62468778","display_name":"New England Journal of Medicine","issn_l":"0028-4793","issn":["0028-4793","0096-6762","1533-4406","2331-4710"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320239","host_organization_name":"Massachusetts Medical Society","host_organization_lineage":["https://openalex.org/P4310320239"],"host_organization_lineage_names":["Massachusetts Medical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"New England Journal of Medicine","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W1802218256.pdf","grobid_xml":"https://content.openalex.org/works/W1802218256.grobid-xml"},"referenced_works_count":25,"referenced_works":["https://openalex.org/W25541533","https://openalex.org/W109974915","https://openalex.org/W1601975653","https://openalex.org/W1789824814","https://openalex.org/W1846134661","https://openalex.org/W1964119221","https://openalex.org/W1976409243","https://openalex.org/W1978139448","https://openalex.org/W1983763042","https://openalex.org/W1997324775","https://openalex.org/W2004643661","https://openalex.org/W2035353185","https://openalex.org/W2037623358","https://openalex.org/W2054728198","https://openalex.org/W2056285082","https://openalex.org/W2059265707","https://openalex.org/W2075086348","https://openalex.org/W2075634939","https://openalex.org/W2091534585","https://openalex.org/W2094739999","https://openalex.org/W2098155102","https://openalex.org/W2137893922","https://openalex.org/W2147517706","https://openalex.org/W2324588265","https://openalex.org/W2396393345"],"related_works":["https://openalex.org/W1842385511","https://openalex.org/W2403486051","https://openalex.org/W2418126227","https://openalex.org/W2159841299","https://openalex.org/W2002673482","https://openalex.org/W2463566778","https://openalex.org/W1553160311","https://openalex.org/W1999335460","https://openalex.org/W2085312730","https://openalex.org/W4299476659"],"abstract_inverted_index":{"BACKGROUND:":[0],"Pegaptanib,":[1],"an":[2,330],"anti-vascular":[3],"endothelial":[4],"growth":[5],"factor":[6],"therapy,":[7],"was":[8,73,108,194,267],"evaluated":[9],"in":[10,199,206,270,320],"the":[11,74,93,97,122,132,143,152,177,200,207,248,256,277,291,303],"treatment":[12],"of":[13,42,47,66,76,85,96,104,118,124,134,145,161,168,182,185,189,212,265,286,317,323],"neovascular":[14,334],"age-related":[15,335],"macular":[16,336],"degeneration.":[17,337],"METHODS:":[18],"We":[19],"conducted":[20],"two":[21],"concurrent,":[22],"prospective,":[23],"randomized,":[24],"double-blind,":[25],"multicenter,":[26],"dose-ranging,":[27],"controlled":[28],"clinical":[29],"trials":[30],"using":[31],"broad":[32],"entry":[33],"criteria.":[34],"Intravitreous":[35],"injection":[36],"into":[37],"one":[38],"eye":[39],"per":[40],"patient":[41],"pegaptanib":[43,119,155,213,218,266],"(at":[44],"a":[45,64,102,111,314],"dose":[46],"0.3":[48,125,157,210,263],"mg,":[49,51,158],"1.0":[50,135],"or":[52,55,192,230],"3.0":[53,146],"mg)":[54],"sham":[56,128,138,149,224,273],"injections":[57,274],"were":[58,302,311],"administered":[59],"every":[60],"6":[61],"weeks":[62,243],"over":[63],"period":[65],"48":[67],"weeks.":[68,90],"The":[69,180],"primary":[70,98],"end":[71,99],"point":[72,100],"proportion":[75],"patients":[77,162,216,261],"who":[78],"had":[79],"lost":[80,163],"fewer":[81,164],"than":[82,165,269],"15":[83,166],"letters":[84,167,191],"visual":[86,169,186,228,258,318],"acuity":[87,187,229,232,259,319],"at":[88,156,252],"54":[89],"RESULTS:":[91],"In":[92,151],"combined":[94],"analysis":[95],"(for":[101],"total":[103],"1186":[105],"patients),":[106,287],"efficacy":[107],"demonstrated,":[109],"without":[110],"dose-response":[112],"relationship,":[113],"for":[114,121,131,142,333],"all":[115,253],"three":[116],"doses":[117],"(P<0.001":[120],"comparison":[123,133,144],"mg":[126,136,147,211,264],"with":[127,137,148,173,223,247,313],"injection;":[129,139],"P<0.001":[130],"and":[140,251,296,306],"P=0.03":[141],"injection).":[150],"group":[153,202,208],"given":[154],"70":[159],"percent":[160,175,198,205,234,285,322],"acuity,":[170],"as":[171,221,241],"compared":[172,222],"55":[174],"among":[176,260],"controls":[178],"(P<0.001).":[179,214],"risk":[181],"severe":[183,315],"loss":[184,316],"(loss":[188],"30":[190],"more)":[193],"reduced":[195],"from":[196],"22":[197],"sham-injection":[201],"to":[203,290,328],"10":[204],"receiving":[209,217,262,272],"More":[215],"(0.3":[219],"mg),":[220],"injection,":[225],"maintained":[226],"their":[227],"gained":[231],"(33":[233],"vs.":[235],"23":[236],"percent;":[237],"P=0.003).":[238],"As":[239],"early":[240],"six":[242],"after":[244],"beginning":[245],"therapy":[246,332],"study":[249],"drug,":[250],"subsequent":[254],"points,":[255],"mean":[257],"better":[268],"those":[271],"(P<0.002).":[275],"Among":[276],"adverse":[278],"events":[279,310],"that":[280],"occurred,":[281],"endophthalmitis":[282],"(in":[283,293,299],"1.3":[284],"traumatic":[288],"injury":[289],"lens":[292],"0.7":[294],"percent),":[295],"retinal":[297],"detachment":[298],"0.6":[300],"percent)":[301],"most":[304],"serious":[305],"required":[307],"vigilance.":[308],"These":[309],"associated":[312],"0.1":[321],"patients.":[324],"CONCLUSIONS:":[325],"Pegaptanib":[326],"appears":[327],"be":[329],"effective":[331],"Its":[338],"long-term":[339],"safety":[340],"is":[341],"not":[342],"known.":[343]},"counts_by_year":[{"year":2026,"cited_by_count":52},{"year":2025,"cited_by_count":77},{"year":2024,"cited_by_count":60},{"year":2023,"cited_by_count":72},{"year":2022,"cited_by_count":57},{"year":2021,"cited_by_count":64},{"year":2020,"cited_by_count":62},{"year":2019,"cited_by_count":56},{"year":2018,"cited_by_count":63},{"year":2017,"cited_by_count":64},{"year":2016,"cited_by_count":75},{"year":2015,"cited_by_count":87},{"year":2014,"cited_by_count":120},{"year":2013,"cited_by_count":108},{"year":2012,"cited_by_count":140}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}